[
    [
        {
            "time": "2021-07-30",
            "original_text": "招银证券：天坛生物(600161.SH)Q2业绩环比改善 预计全年业绩提速 维持“审慎推荐-A”评级",
            "features": {
                "keywords": [
                    "天坛生物",
                    "Q2业绩",
                    "环比改善",
                    "全年业绩提速",
                    "审慎推荐-A"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "招银证券：天坛生物(600161.SH)Q2业绩环比改善 预计全年业绩提速 维持“审慎推荐-A”评级",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "2021-08-05",
            "original_text": "太平洋维持天坛生物买入评级：业绩超预期，浆源获取能力强，浆量具备持续成长性",
            "features": {
                "keywords": [
                    "天坛生物",
                    "买入评级",
                    "业绩超预期",
                    "浆源获取能力",
                    "持续成长性"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "太平洋维持天坛生物买入评级：业绩超预期，浆源获取能力强，浆量具备持续成长性",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2021-08-10",
            "original_text": "天坛生物（600161）2021H1业绩快报点评：业绩超预期，血制品业务增长潜力大！【东吴医药朱国广团队】",
            "features": {
                "keywords": [
                    "天坛生物",
                    "2021H1业绩",
                    "业绩超预期",
                    "血制品业务",
                    "增长潜力大"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "天坛生物（600161）2021H1业绩快报点评：业绩超预期，血制品业务增长潜力大！【东吴医药朱国广团队】",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 9,
                "Source_Recency": 4
            }
        },
        {
            "time": "2021-08-15",
            "original_text": "东吴证券维持天坛生物买入评级，2021上半年业绩快报点评：业绩超预期，血制品业务增长潜力大",
            "features": {
                "keywords": [
                    "东吴证券",
                    "天坛生物",
                    "买入评级",
                    "2021上半年业绩",
                    "业绩超预期",
                    "血制品业务",
                    "增长潜力大"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "东吴证券维持天坛生物买入评级，2021上半年业绩快报点评：业绩超预期，血制品业务增长潜力大",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 4
            }
        }
    ]
]